CN1150029C - 抗生素的给药方法 - Google Patents

抗生素的给药方法 Download PDF

Info

Publication number
CN1150029C
CN1150029C CNB998124982A CN99812498A CN1150029C CN 1150029 C CN1150029 C CN 1150029C CN B998124982 A CNB998124982 A CN B998124982A CN 99812498 A CN99812498 A CN 99812498A CN 1150029 C CN1150029 C CN 1150029C
Authority
CN
China
Prior art keywords
daptomycin
dosage
purposes according
hours
antibiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CNB998124982A
Other languages
English (en)
Chinese (zh)
Other versions
CN1348382A (zh
Inventor
F��B��С����ɭ
F·B·小奥莱森
F·P·塔利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cubist Pharmaceuticals LLC
Original Assignee
Cubist Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1150029(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals LLC filed Critical Cubist Pharmaceuticals LLC
Publication of CN1348382A publication Critical patent/CN1348382A/zh
Application granted granted Critical
Publication of CN1150029C publication Critical patent/CN1150029C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
CNB998124982A 1998-09-25 1999-09-24 抗生素的给药方法 Ceased CN1150029C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US12575099P 1999-03-24 1999-03-24
US60/125,750 1999-03-24
US60/101,828 1999-03-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA200410031708XA Division CN1530136A (zh) 1998-09-25 1999-09-24 抗生素的给药方法

Publications (2)

Publication Number Publication Date
CN1348382A CN1348382A (zh) 2002-05-08
CN1150029C true CN1150029C (zh) 2004-05-19

Family

ID=26798675

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB998124982A Ceased CN1150029C (zh) 1998-09-25 1999-09-24 抗生素的给药方法
CNA200410031708XA Pending CN1530136A (zh) 1998-09-25 1999-09-24 抗生素的给药方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA200410031708XA Pending CN1530136A (zh) 1998-09-25 1999-09-24 抗生素的给药方法

Country Status (26)

Country Link
US (2) US6468967B1 (enExample)
EP (2) EP1674107B8 (enExample)
JP (4) JP4184607B2 (enExample)
KR (2) KR20100051735A (enExample)
CN (2) CN1150029C (enExample)
AT (1) ATE322280T1 (enExample)
AU (1) AU764348B2 (enExample)
BR (1) BR9914051A (enExample)
CA (1) CA2344318C (enExample)
CY (3) CY1105556T1 (enExample)
DE (3) DE69930758T2 (enExample)
DK (2) DK1674107T3 (enExample)
ES (2) ES2603086T3 (enExample)
HK (1) HK1040363B (enExample)
HU (1) HU230656B1 (enExample)
IS (2) IS5890A (enExample)
LU (1) LU91254I2 (enExample)
NL (1) NL300232I2 (enExample)
NO (1) NO20011454L (enExample)
NZ (1) NZ510690A (enExample)
PL (2) PL203689B1 (enExample)
PT (2) PT1115417E (enExample)
RU (1) RU2363489C9 (enExample)
SI (2) SI1115417T1 (enExample)
TR (1) TR200100841T2 (enExample)
WO (1) WO2000018419A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674107B8 (en) 1998-09-25 2017-01-25 Cubist Pharmaceuticals LLC Use of daptomycin
US6911525B2 (en) 1999-12-15 2005-06-28 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
WO2002056829A2 (en) 2000-12-18 2002-07-25 Cubist Pharmaceuticals, Inc. Methods for preparing purified daptomycin
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
AU2003274927A1 (en) * 2002-08-23 2004-03-11 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (en) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
WO2009111422A2 (en) * 2008-03-04 2009-09-11 Elan Pharmaceuticals, Inc. Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
AU2009292216B2 (en) 2008-07-17 2015-03-05 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
US8629139B2 (en) 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
CA2739897C (en) 2008-10-07 2017-10-03 Mpex Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics
WO2010048630A1 (en) * 2008-10-24 2010-04-29 Los Angeles Biomedical Reserch Institute At Harbor-Ucla Medical Center Anti-infective hydroxy-phenyl-benzoates and methods of use
PT2379580E (pt) 2008-12-22 2014-01-20 Cubist Pharm Inc Novos agentes antibacterianos para o tratamento de infecções por bactérias gram positivas
TW201035111A (en) 2008-12-23 2010-10-01 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
CA2767614C (en) * 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
EP2473170B1 (en) 2009-09-04 2019-06-19 Horizon Orphan LLC Use of aerosolized levofloxacin for treating cystic fibrosis
TWI606838B (zh) 2009-11-23 2017-12-01 庫比斯特製藥有限責任公司 達托黴素（ｄａｐｔｏｍｙｃｉｎ）組合物及相關方法
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2013059610A1 (en) * 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
MX2014011827A (es) 2012-03-30 2015-02-20 Cubist Pharm Inc Inhibidores de 1,3,4 - oxadiazol y 1,3,4 - tiadiazol b-lactamasa.
EP4066849B1 (en) * 2012-09-11 2025-03-05 Hospira Australia Pty Ltd Daptomycin formulations and uses thereof
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
TWI641372B (zh) 2013-03-15 2018-11-21 美商梅琳塔有限責任公司 使用抗生素治療超重和肥胖患者感染的方法
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US20190209645A1 (en) * 2016-05-13 2019-07-11 Spero Potentiator, Inc. Potentiation of antibiotic activity by a novel cationic peptide, spr741
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
CA1315229C (en) 1987-06-10 1993-03-30 Patrick J. Baker Chromatographic purification process
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
FR2755857B1 (fr) 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
EP1674107B8 (en) 1998-09-25 2017-01-25 Cubist Pharmaceuticals LLC Use of daptomycin
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Also Published As

Publication number Publication date
IS8807A (is) 2009-03-10
SI1115417T1 (sl) 2006-08-31
CY2006003I2 (el) 2009-11-04
NO20011454L (no) 2001-05-25
WO2000018419A2 (en) 2000-04-06
CY1118334T1 (el) 2017-06-28
HU230656B1 (hu) 2017-06-28
EP1115417A2 (en) 2001-07-18
NL300232I1 (nl) 2006-09-01
NL300232I2 (nl) 2007-01-02
HUP0103874A3 (en) 2002-09-30
PL348328A1 (en) 2002-05-20
HK1040363A1 (en) 2002-06-07
EP1674107A2 (en) 2006-06-28
CA2344318C (en) 2006-07-04
EP1674107A8 (en) 2006-10-04
ES2603086T3 (es) 2017-02-23
DE69930758D1 (de) 2006-05-18
RU2363489C2 (ru) 2009-08-10
KR20100051735A (ko) 2010-05-17
PT1674107T (pt) 2016-12-07
JP2006335773A (ja) 2006-12-14
EP1674107A3 (en) 2012-06-20
HK1040363B (en) 2007-01-26
SI1674107T1 (sl) 2017-01-31
NZ510690A (en) 2002-10-25
KR20010075327A (ko) 2001-08-09
RU2363489C9 (ru) 2010-03-20
CY2006003I1 (el) 2009-11-04
IS5890A (is) 2001-03-14
US6468967B1 (en) 2002-10-22
AU6268799A (en) 2000-04-17
CN1348382A (zh) 2002-05-08
RU2004106569A (ru) 2005-08-10
DE69930758T2 (de) 2007-04-26
BR9914051A (pt) 2001-06-19
CA2344318A1 (en) 2000-04-06
EP1115417B1 (en) 2006-04-05
US6852689B2 (en) 2005-02-08
US20020142948A1 (en) 2002-10-03
JP4184607B2 (ja) 2008-11-19
DE122006000049I1 (de) 2007-01-04
CN1530136A (zh) 2004-09-22
PL206091B1 (pl) 2010-06-30
ATE322280T1 (de) 2006-04-15
JP2003321389A (ja) 2003-11-11
JP2004339238A (ja) 2004-12-02
DK1115417T3 (da) 2006-07-31
JP2002525335A (ja) 2002-08-13
LU91254I2 (fr) 2006-08-28
PL203689B1 (pl) 2009-11-30
DE122006000049I2 (de) 2007-11-08
TR200100841T2 (tr) 2002-01-21
CY1105556T1 (el) 2010-07-28
EP1674107B8 (en) 2017-01-25
AU764348B2 (en) 2003-08-14
NO20011454D0 (no) 2001-03-22
PT1115417E (pt) 2006-07-31
ES2259845T3 (es) 2006-10-16
WO2000018419A3 (en) 2000-07-06
DK1674107T3 (en) 2016-12-19
EP1674107B1 (en) 2016-08-24
HUP0103874A2 (hu) 2002-02-28

Similar Documents

Publication Publication Date Title
CN1150029C (zh) 抗生素的给药方法
Tedesco et al. Daptomycin
Willcocks et al. Revisiting aminocoumarins for the treatment of melioidosis
CA2887388C (en) Combinations with a backbone-cyclized peptide
RU2232592C2 (ru) Способ лечения бактериальной инфекции
Ross et al. Glycopeptide pharmacodynamics
ES2949169T3 (es) Procedimientos para tratar la bacteriemia y la osteomielitis utilizando oritavancina
US20040023857A1 (en) Treatment of rosacea
CZ20011014A3 (cs) Farmaceutické přípravky obsahující lipoproteinová antibiotika
HK1094672A (en) Use of daptomycin
CN107847501A (zh) 抗菌组合物以及方法
EA007713B1 (ru) Ассоциации дальфопристин/хинупристин с цефпиромом
Jacqueline et al. Antibiotics Against Endocarditis–Past, Present and Future (Experimental Data)

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C35 Partial or whole invalidation of patent or utility model
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20090422

Decision number of declaring invalidation: 13188

Granted publication date: 20040519